New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
11:46 EDTCYBXCyberonics rallies after former employee drops lawsuit
Cyberonics (CYBX), which develops nerve stimulation devices that are supposed to combat epilepsy and depression, is rising after former employee Andrew Hagerty dropped his lawsuit against the company on February 2. Hagerty, a former sales representative at Cyberonics, had alleged that he was improperly fired by the company, Jefferies analyst Raj Denhoy wrote in a note to investors earlier today. Moreover, Hagerty stated that Cyberonics had committed significant "broad-based improprieties," according to Denhoy. Hagerty alleged that Cyberonics had systematically committed fraud by coercing surgeons to prematurely remove the batteries from Cyberonics devices implanted in patients, short-selling blog TheStreetSweeper reported last month. Hagerty's decision to terminate the lawsuit removes an overhang from Cyberonics shares, wrote Jefferies' Denhoy, who reiterated a Buy rating on the stock. In late morning trading, Cyberonics jumped $4.37, or 10%, to $48.72.
News For CYBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
11:51 EDTCYBXCyberonics reports new results from E-36, E-37 studies
Cyberonics announced new results from two multi-site clinical studies of the AspireSR generator, E-36 and E-37, at the AES Annual Meeting in Seattle, Washington. Investigators presented results from the European E-36 study and the U.S. E-37 study, which assessed the acute impact of the AspireSR generator on seizure duration and termination, as well as the long-term evaluation of safety, clinical benefit of the automatic stimulation feature, and quality of life. Assessments of seizure severity and quality of life were made using validated scales scored by patients and physicians. The acute impact of the AspireSR generator on seizure duration and termination was evaluated during the Epilepsy Monitoring Unit stay period experienced by all patients in both studies. Seizure activity was recorded using concurrent video-EEG and ECG monitoring. Patients in both studies experienced termination of seizures as well as reduced seizure duration during automatic stimulation compared to historical controls. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use